<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03911505</url>
  </required_header>
  <id_info>
    <org_study_id>ATB200-04</org_study_id>
    <nct_id>NCT03911505</nct_id>
  </id_info>
  <brief_title>ZIP Study - A Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of ATB200/AT2221 in Pediatric Subjects Aged 0 to &lt; 18 Years With Pompe Disease</brief_title>
  <official_title>An Open-label Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of ATB200/AT2221 in Pediatric Subjects Aged 0 to &lt; 18 Years With Pompe Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amicus Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amicus Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD,&#xD;
      and immunogenicity of ATB200/AT2221 treatment in enzyme replacement therapy (ERT)-experienced&#xD;
      and ERT-naïve pediatric subjects with Pompe disease, aged 0 to &lt; 18 years&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2020</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) from baseline</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameters</measure>
    <time_frame>52 weeks</time_frame>
    <description>ATB200 and AT2221 concentrations in plasma</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Pompe Disease (Late-onset)</condition>
  <arm_group>
    <arm_group_label>Cipaglucosidase Alfa (ATB200)/Miglustat(AT2221)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat (AT2221) capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cipaglucosidase Alfa</intervention_name>
    <description>Enzyme Replacement Therapy via intravenous infusion</description>
    <arm_group_label>Cipaglucosidase Alfa (ATB200)/Miglustat(AT2221)</arm_group_label>
    <other_name>ATB200</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miglustat</intervention_name>
    <description>Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat(AT2221)</description>
    <arm_group_label>Cipaglucosidase Alfa (ATB200)/Miglustat(AT2221)</arm_group_label>
    <other_name>AT2221</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects (ERT-naïve [have never received a dose of rhGAA] or&#xD;
             ERT-experienced [have received rhGAA every 2 weeks for at least 6 months immediately&#xD;
             before enrollment, and if ERT dosage has been modified, must have been on the modified&#xD;
             dosage for at least 3 months before enrollment]) diagnosed with LOPD who are aged 12&#xD;
             to &lt;18 years at screening (Cohort 1 only) or aged 0 months to &lt; 12 years at screening&#xD;
             (Cohort 2 only)&#xD;
&#xD;
          2. Subject weighs ≥ 25 kg and ≤ 115 kg. (Cohort 1 Only)&#xD;
&#xD;
          3. Subject must have a diagnosis of LOPD based on documentation as defined in study&#xD;
             protocol&#xD;
&#xD;
          4. If of reproductive potential and if sexually active, female and male subjects agree to&#xD;
             use a highly effective method of contraception throughout the duration of the study&#xD;
             and for up to 90 days after their last dose of ATB200/AT2221&#xD;
&#xD;
          5. Subject has a sitting forced vital capacity (FVC) ≥ 30% of the predicted value for&#xD;
             healthy Adolescents at screening (Cohort 1 only)&#xD;
&#xD;
          6. Subject (aged 12 to &lt;18 years; Cohort 1) performs one 6-Minute Walk Test (6MWT) (≥ 75&#xD;
             meters) at screening that is valid, as determined by the clinical evaluator, or&#xD;
             subject (aged ≥ 5 to &lt; 12 years; Cohort 2) performs one 6MWT (≥ 40 meters) at&#xD;
             screening that is valid, as determined by the clinical evaluator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has received any investigational/experimental drug, oral anabolic steroid or&#xD;
             derivative, biologic, or device within 30 days or 5 half-lives of the therapy or&#xD;
             treatment, whichever is longer, before screening&#xD;
&#xD;
          2. Subject has received treatment with prohibited medications within 30 days of screening&#xD;
&#xD;
          3. Subject has received any gene therapy at any time&#xD;
&#xD;
          4. Subject has any intercurrent illness or condition at screening or baseline that may&#xD;
             preclude the subject from fulfilling the protocol requirements or suggests to the&#xD;
             investigator and/or the medical monitor that the potential subject may have an&#xD;
             unacceptable risk by participating in this study&#xD;
&#xD;
          5. Subject has a hypersensitivity to any of the excipients in ATB200, approved rhGAA, or&#xD;
             AT2221&#xD;
&#xD;
          6. Female subject is pregnant or breast-feeding at screening&#xD;
&#xD;
          7. Subject requires the use of ventilation support for &gt; 6 hours per day while awake&#xD;
&#xD;
          8. Subject has evidence of moderate to severe hypertrophic cardiomyopathy aligning with&#xD;
             classic IOPD&#xD;
&#xD;
          9. In the opinion of the investigator, the parent or legally authorized representative is&#xD;
             unlikely or unable to comply with the study requirements&#xD;
&#xD;
         10. Subject has any prior history of illness or condition known to affect motor function,&#xD;
             such as, but not limited to, Guillain-Barre syndrome, cerebral palsy, etc&#xD;
&#xD;
         11. Subject who is diagnosed with Pompe disease via newborn screening and is asymptomatic&#xD;
             (ie, showing no signs and symptoms of Pompe disease (Cohort 2 Only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>For Site</last_name>
    <phone>215-921-7600</phone>
    <email>PompeSiteInfo@amicusrx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>For Patient</last_name>
    <phone>215-921-7600</phone>
    <email>patientadvocacy@amicusrx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Neuromuscular Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida Clinical Research Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Infusion Associates</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lysosomal and Rare Disorders Research and Treatment Center, Inc.</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gunma University Hospital</name>
      <address>
        <city>Gunma</city>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Miyagi</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Japan</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 9, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pompe</keyword>
  <keyword>rhGAA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miglustat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

